TG Therapeutics Inc (TGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TG Therapeutics Inc (TGTX) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.89 Million) by net assets ($583.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TGTX days of operational coverage to measure how many days the company can operate on defensive assets alone.
TG Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how TG Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TG Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TG Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Daqo New Energy Co Ltd
SHG:688303
|
0.002x |
|
Cleveland-Cliffs Inc
NYSE:CLF
|
-0.054x |
|
Railway Signal Communication Ltd
SHG:688009
|
0.013x |
|
Zheshang Securities Co Ltd
SHG:601878
|
0.140x |
|
OUTSURANCE GROUP LTD
JSE:OUT
|
0.297x |
|
Rayonier Inc
NYSE:RYN
|
0.116x |
|
Glacier Bancorp Inc
NYSE:GBCI
|
0.021x |
|
Hengdian Group DMEGC Magnetics Co Ltd
SHE:002056
|
0.120x |
Annual Cash Flow Conversion Efficiency for TG Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of TG Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see how much is TG Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $648.02 Million | $-24.77 Million | -0.038x | +79.02% |
| 2024-12-31 | $222.36 Million | $-40.52 Million | -0.182x | +6.90% |
| 2023-12-31 | $160.50 Million | $-31.41 Million | -0.196x | +93.49% |
| 2022-12-31 | $58.59 Million | $-176.17 Million | -3.007x | -141.22% |
| 2021-12-31 | $237.15 Million | $-295.63 Million | -1.247x | -201.82% |
| 2020-12-31 | $519.35 Million | $-214.51 Million | -0.413x | +87.99% |
| 2019-12-31 | $38.62 Million | $-132.81 Million | -3.439x | +35.88% |
| 2018-12-31 | $24.04 Million | $-128.93 Million | -5.364x | -- |
| 2017-12-31 | $0.00 | $-93.76 Million | x | -- |
| 2016-12-31 | $0.00 | $-61.59 Million | x | -- |
| 2015-12-31 | $0.00 | $-44.69 Million | x | -- |
| 2014-12-31 | $0.00 | $-35.06 Million | x | -- |
| 2013-12-31 | $0.00 | $-10.82 Million | x | -- |
| 2012-12-31 | $15.55 Million | $-5.19 Million | -0.334x | -3613.31% |
| 2011-12-31 | $9.64 Million | $-86.58K | -0.009x | -102.45% |
| 2010-12-31 | $-5.36 Million | $-1.97 Million | 0.367x | +137.37% |
| 2009-12-31 | $-6.78 Million | $-1.05 Million | 0.155x | -84.76% |
| 2008-12-31 | $-4.38 Million | $-4.44 Million | 1.016x | -91.15% |
| 2007-12-31 | $-891.09K | $-10.23 Million | 11.480x | +322.86% |
| 2006-12-31 | $1.50 Million | $-7.75 Million | -5.151x | -686.97% |
| 2005-12-31 | $9.54 Million | $-6.24 Million | -0.655x | +48.77% |
| 2004-12-31 | $4.45 Million | $-5.69 Million | -1.278x | -152.94% |
| 2003-12-31 | $6.83 Million | $-3.45 Million | -0.505x | -111.53% |
| 2002-12-31 | $-326.99K | $-1.43 Million | 4.381x | +222.37% |
| 2001-12-31 | $1.25 Million | $-4.47 Million | -3.580x | -240.33% |
| 2000-12-31 | $1.10 Million | $-1.15 Million | -1.052x | -55.51% |
| 1999-12-31 | $3.40 Million | $-2.30 Million | -0.676x | -53.51% |
| 1998-12-31 | $5.90 Million | $-2.60 Million | -0.441x | +9.71% |
| 1997-12-31 | $8.40 Million | $-4.10 Million | -0.488x | +74.37% |
| 1996-12-31 | $2.10 Million | $-4.00 Million | -1.905x | -- |
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolat… Read more